Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Brain Neoplasms 365Glioblastoma 300Glioma 238Neuroblastoma 94Neoplasms 70Central Nervous System Neoplasms 62Astrocytoma 61Meningioma 59Breast Neoplasms 51Lung Neoplasms 46Carcinoma, Non-Small-Cell Lung 46Melanoma 40Sarcoma 35Medulloblastoma 33Meningeal Carcinomatosis 32Recurrence 31Neoplasm Metastasis 28Diffuse Intrinsic Pontine Glioma 28Prostatic Neoplasms 27Pheochromocytoma 26Paraganglioma 26Neurofibromatosis 1 25Pancreatic Neoplasms 24Ovarian Neoplasms 24Oligodendroglioma 21Ependymoma 21Osteosarcoma 20Head and Neck Neoplasms 20Spinal Cord Neoplasms 19Kidney Neoplasms 19

Interventions

Sufentanil 1((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Postoperative Nausea and Vomiting × CNS × Clear all
NCT07479446 2026-05-22

Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

Xuanwu Hospital, Beijing

Phase NA Recruiting
174 enrolled
CNS

Neuroma, Acoustic, Postoperative Nausea and Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡